VYNT
Vyant Bio, Inc. [VYNT] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VYNT Stock Summary
In the News
VYNT Financial details
Company Rating
-
Market Cap
1.23M
Income
-28.71M
Revenue
666K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
29 Mar 2024
P/E
-0.08
Forward P/E
-
PEG
0.02
P/S
6.2
P/B
0.11
P/C
-
P/FCF
-0.21
Quick Ratio
2.83
Current Ratio
3.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.9
EPS next Y
-
EPS next Q
-
EPS this Y
-62.02%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-48.98%
Revenue last 5Y
-52.47%
Revenue Q/Q
-69.74%
EPS Q/Q
203.45%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-90%
ROE
-116%
ROC
-0.62%
Gross Margin
-61%
Oper. Margin
-3626%
Profit Margin
-6940%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.141-1.58
52W High
-
52W Low
-
RSI
46
Rel Volume
1.07
Avg Volume
17.86K
Volume
19.12K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.56
-
-
Volatility
0.03%, 0.03%
Prev Close
-25.38%
Price
0.194
Change
-
Company Profile
- Volume Average 17.86K
- Market Capitalization 1.23M
- Employee 4
- CEO Mr. Andrew D.C. LaFrence CPA
- Headquarters Cherry Hill,NJ,US
- IPO Date 2021-04-01
-
Website
https://www.vyantbio.com 
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
